Compass Therapeutics, Inc. - 10-Q Filing

Compass Therapeutics reports Q3 2026 financial results including research and development expense breakdowns across CTX programs.

SEC EDGAR ·

Tickers: $CMPX

Read the full article at SEC EDGAR

More Regulatory news